Sacituzumab

Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2) . Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254) . Sacituzumab govitecan can be used in the field of triple-negative breast cancer[1][2][3][4].

Product Specifications

CAS Number

[1796566-95-4]

Product Name Alternative

HRS7

UNSPSC

12352203

Target

ADC Antibody; TROP2

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sacituzumab.html

Purity

99.86

Solubility

H2O

Smiles

[Sacituzumab]

Molecular Weight

(145.52 kDa)

References & Citations

[1]Bardia A, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32 (9) :1148-1156.|[2]Zhou DD, et al. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2[J]. Int J Biol Macromol. 2023 Dec 31;253 (Pt 6) :127105.|[3]Sun M, et al. Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2[J]. iScience. 2021 Sep 30;24 (10) :103190. |[4]Shih LB, et al. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer[J]. Cancer Res. 1995 Dec 1;55 (23 Suppl) :5857s-5863s.